Microbe Report: MRSA

Microbe Report: MRSA. Name Date

1

09/30/2023

CASE STUDY

Image: Raghavan (2017)

2

09/30/2023

Microbe Analysis

Image: CDC (2019).

3

09/30/2023

Microbe type and description

*

Image: (Kong, ohnson & Jabra-Rizk, 2016).

4

09/30/2023

Symptoms of the disease Image: (CDC, 2019)

Image: (CDC, 2019)

Image: (CDC, 2019)

5

09/30/2023

Epidemiology

Image ((Craft, Nguyen, Berg & Townsend, 2019).

Image (Junnila, 2020)

6

09/30/2023

Treatment and New Research

Image: (Hua, et al., 2018).

7

09/30/2023

References

 CDC (2019). Methicillin-resistant Staphylococcus aureus (MRSA). https://www.cdc.gov/mrsa/community/photos/photo-mrsa-1.html  Choo, E. J., & Chambers, H. F. (2016). Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Infection & chemotherapy, 48(4), 267–273. https://doi.org/10.3947/ic.2016.48.4.267  Craft, K. M., Nguyen, J. M., Berg, L. J., & Townsend, S. D. (2019). Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype. MedChemComm, 10(8), 1231-1241.  Craft, K. M., Nguyen, J. M., Berg, L. J., & Townsend, S. D. (2019). Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype. MedChemComm, 10(8), 1231-1241. https://pubs.rsc.org/en/content/articlelanding/2019/md/c9md00044e#!divAbstract  Enany, S., & Alexander, L. C. (Eds.). (2017). The Rise of Virulence and Antibiotic Resistance in Staphylococcus aureus. BoD–Books on Demand.  Hua, X., Yang, Q., Zhang, W., Dong, Z., Yu, S., Schwarz, S., & Liu, S. (2018). Antibacterial activity and mechanism of action of aspidinol against multi-drug-resistant methicillin-resistant Staphylococcus aureus. Frontiers in pharmacology, 9, 619. https://doi.org/10.3389/fphar.2018.00619  Ji, Y. (Ed.). (2020). Methicillin-resistant Staphylococcus Aureus (MRSA) Protocols: Cutting-edge Technologies and Advancements. Humana Press.  Junnila, J., Hirvioja, T., Rintala, E., Auranen, K., Rantakokko-Jalava, K., Silvola, J., ... & Vuopio, J. (2020). Changing epidemiology of methicillinresistant Staphylococcus aureus in a low endemicity area—new challenges for MRSA control. European Journal of Clinical Microbiology & Infectious Diseases, 1-9. https://doi.org/10.1007/s10096-020-03824-9  Kong, E. F., Johnson, J. K., & Jabra-Rizk, M. A. (2016). Community-associated methicillin-resistant Staphylococcus aureus: an enemy amidst us. PLoS pathogens, 12(10), e1005837. https://doi.org/10.1371/journal.ppat.1005837  Labreure, R., Sona, A. J., & Turos, E. (2019). Anti-methicillin resistant Staphylococcus aureus (MRSA) nanoantibiotics. Frontiers in pharmacology, 10, 1121. https://doi.org/10.3389/fphar.2019.01121  Lakhundi, S., & Zhang, K. (2018). Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology.

Clinical microbiology reviews, 31(4). 18 http://DOI:10.1128/CMR.00020-18  Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018). Methicillin-resistant Staphylococcus aureus. Nature reviews Disease primers, 4(1), 1-23.  Raghavan, P. R., (2017). Metadichol® and MRSA Infections: A Case Report. Journal of Infectious Diseases Therapy, 5: 317. http://doi:10.4172/2332-0877.1000317  Henderson, A., & Nimmo, G. R. (2018). Control of healthcare-and community-associated MRSA: recent progress and persisting challenges.

British medical bulletin, 125(1), 25-41. https://doi.org/10.1093/bmb/ldx046 09/30/2023